Literature DB >> 16142575

Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease.

Shuling Li1, Robert N Foley, Allan J Collins.   

Abstract

BACKGROUND: Large observational studies examining the association between anemia and "hard" clinical outcomes are rare in patients with chronic kidney disease (CKD).
METHODS: We used the General Medicare 5% Denominator Files to identify patients aged 67 years or more with CKD on December 31, 1999. Outcomes in the ensuing 2 years were compared in patients with and those without anemia (entry period, 1998-1999; follow-up period, 2000-2001).
RESULTS: Of 41,522 CKD patients identified, 49.0% had claims of anemia diagnosis. The factors associated (p< 0.0001) with anemia included older age, female gender, black race, and all 10 comorbid conditions studied; adjusted odds ratios (ORs) exceeded 1.5 for age 80 years old or older (OR, 1.54 compared to <70 years), for black race (OR, 1.52), and for co-existing diagnoses of congestive heart failure (OR, 1.64), gastrointestinal bleeding (OR, 3.65), and liver disease (OR, 2.16). During the follow-up period, outcome event rates (expressed per 1000 patient-years) were as follows: renal replacement therapy, 23.5; death, 186.4; congestive heart failure, 390.0; atherosclerotic vascular disease, 410.5; and first hospitalization, 552.6. Using proportional hazards modeling, the presence of anemia was associated (p < 0.0001) with the following adjusted hazards ratios: atherosclerotic vascular disease, 1.09; congestive heart failure, 1.14; renal replacement therapy, 2.61 and death, 1.40.
CONCLUSION: A diagnosis of anemia is present in nearly half of all patients with CKD, aged 67 years or more, a group at very high risk of cardiovascular disease, hospitalization, end-stage renal disease, and death. Anemia is associated with each of these events.

Entities:  

Mesh:

Year:  2005        PMID: 16142575     DOI: 10.1007/s11255-004-3068-2

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  41 in total

1.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.

Authors:  A Levin; C R Thompson; J Ethier; E J Carlisle; S Tobe; D Mendelssohn; E Burgess; K Jindal; B Barrett; J Singer; O Djurdjev
Journal:  Am J Kidney Dis       Date:  1999-07       Impact factor: 8.860

2.  The hemodynamic response to chronic anemia.

Authors:  M Duke; W H Abelmann
Journal:  Circulation       Date:  1969-04       Impact factor: 29.690

3.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.

Authors:  Tamara B Horwich; Gregg C Fonarow; Michele A Hamilton; W Robb MacLellan; Jeff Borenstein
Journal:  J Am Coll Cardiol       Date:  2002-06-05       Impact factor: 24.094

4.  Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.

Authors:  Donna M Mancini; Stuart D Katz; Chim C Lang; John LaManca; Alhakam Hudaihed; Ana-Silvia Androne
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

5.  Hemodilution is common in patients with advanced heart failure.

Authors:  Ana-Silvia Androne; Stuart D Katz; Lars Lund; John LaManca; Alhakam Hudaihed; Katarzyna Hryniewicz; Donna M Mancini
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

6.  Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin.

Authors:  L P McMahon; J A Johns; A McKenzie; M Austin; R Fowler; J K Dawborn
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

7.  Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated?

Authors:  Paulo H M Chaves; Bimal Ashar; Jack M Guralnik; Linda P Fried
Journal:  J Am Geriatr Soc       Date:  2002-07       Impact factor: 5.562

8.  Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients.

Authors:  D Roth; R D Smith; G Schulman; T I Steinman; F E Hatch; M R Rudnick; J A Sloand; B I Freedman; W W Williams; C A Shadur
Journal:  Am J Kidney Dis       Date:  1994-11       Impact factor: 8.860

Review 9.  Anemia management and the delay of chronic renal failure progression.

Authors:  Jerome Rossert; Bruno Fouqueray; Jean Jacques Boffa
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

10.  Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients.

Authors:  A Sikole; M Polenakovic; V Spirovska; B Polenakovic; G Masin
Journal:  Artif Organs       Date:  1993-12       Impact factor: 3.094

View more
  14 in total

1.  A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial.

Authors:  Brendan J Barrett; Amit X Garg; Ron Goeree; Adeera Levin; Anita Molzahn; Claudio Rigatto; Joel Singer; George Soltys; Steven Soroka; Dieter Ayers; Patrick S Parfrey
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

2.  Prognostic value of estimated glomerular filtration rate in hospitalized elderly patients.

Authors:  Laura De La Higuera; Emma Riva; Codjo Djignefa Djade; Sara Mandelli; Carlotta Franchi; Alessandra Marengoni; Francesco Salerno; Salvatore Corrao; Luca Pasina; Mauro Tettamanti; Maura Marcucci; Pier Mannuccio Mannucci; Alessandro Nobili
Journal:  Intern Emerg Med       Date:  2013-12-14       Impact factor: 3.397

Review 3.  Early detection of CKD: the benefits, limitations and effects on prognosis.

Authors:  Adeera Levin; Paul E Stevens
Journal:  Nat Rev Nephrol       Date:  2011-06-28       Impact factor: 28.314

4.  The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients.

Authors:  Jolanta Malyszko; Edyta Zbroch; Jacek Malyszko; Michal Mysliwiec; Adrian Iaina
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

5.  Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

Authors:  David Goldsmith; Frank Dellanna; Martin Schiestl; Andriy Krendyukov; Christian Combe
Journal:  Clin Drug Investig       Date:  2018-06       Impact factor: 2.859

6.  Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice.

Authors:  Abduzhappar Gaipov; Alpamys Issanov; Zhanar Mursalova; Nazia Tulegenova; Zoya Kakim; Mukhit Baizakov; Saltanat Tuganbekova; Mohamad Aljofan
Journal:  Pharmacol Res Perspect       Date:  2020-06

7.  Anemia and Incident End-Stage Kidney Disease.

Authors:  Santosh L Saraf; Jesse Y Hsu; Ana C Ricardo; Rupal Mehta; Jing Chen; Teresa K Chen; Michael J Fischer; Lee Hamm; James Sondheimer; Matthew R Weir; Xiaoming Zhang; Myles Wolf; James P Lash
Journal:  Kidney360       Date:  2020-07-30

8.  The perception of the illness with subsequent outcome measure in more favorable in continuos peritoneal dialysis vs hemodialysis in the framework of appraisal model of stress.

Authors:  Zbigniew Nowak; Krzysztof Laudański
Journal:  Int J Med Sci       Date:  2014-02-04       Impact factor: 3.738

9.  Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia.

Authors:  Daniel Eriksson; David Goldsmith; Siguroli Teitsson; James Jackson; Floortje van Nooten
Journal:  BMC Nephrol       Date:  2016-07-26       Impact factor: 2.388

10.  Correction of Anemia in Chronic Kidney Disease With Angelica sinensis Polysaccharide via Restoring EPO Production and Improving Iron Availability.

Authors:  Kaiping Wang; Jun Wu; Jingya Xu; Saisai Gu; Qiang Li; Peng Cao; Mingming Li; Yu Zhang; Fang Zeng
Journal:  Front Pharmacol       Date:  2018-07-31       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.